Comparison of Clinical Application Between Tacrolimus and Cyclosporine A in Organ Transplantation
- VernacularTitle:他克莫司与环孢素A在器官移植中的应用比较
- Author:
Xiaoping WEI
;
Li LI
- Publication Type:Journal Article
- Keywords:
Tacrolimus Cyclosporine A Pharmaceutical mechanism Rejection response Organ transplantation
- From:
Chinese Journal of Bases and Clinics in General Surgery
2003;0(04):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare tacrolumus (FK506) with cyclosporine A (CsA) in clinical application to organ transplantation.Methods The literature in recent years has been reviewed and compared. Results FK506 was a powerful immunosuppression with a mechanism of action similar to that of CsA, but significantly superiori to CsA in terms of prophylaxis and treatment of allograft acute rejection, delay of chronic rejection, and withdrawal of steroid in early period. The cardiovascular mortality and chronic graft nephropathy (CGN),such as hypertension and hyperlipidemia were less frequently seen in FK506-treated patients and FK506 also had an acceptable safety profile, including a low incidence of hypertrichosis,gingival hyperplasia and infections.However, CsA had been showed a better result in prevention of posttransplantation diabetes mellitus (PTDM ) and more economic agent than FK506. Pharmacokinetic studies showed CsA in the form of Sandimmun Neoral showed less inter- an intrapatient variability than FK506.Meanwhile, the combination of MMF and FK506 or CsA has been proved effectively with excellent graft and patients survival. Conclusion FK506 and CsA are safe and effective long term maintenance immunosuppressive agents in organ transplantation with wonderful prospect.
